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Abstract
Background: Humanistic burden considers the impact of an illness on a patient’s health-related quality of life (HRQoL),
activities of daily living (ADL), caregiver health, and caregiver QoL. Humanistic burden also considers treatment
satisfaction and adherence to treatment regimens. Pompe disease is an autosomal recessive, progressive, multisystemic
neuromuscular disease. Approval of enzyme-replacement therapy (ERT) markedly improved prognosis for patients, but
considerable morbidity and a substantial humanistic burden remain. This article characterizes the humanistic burden of
Pompe disease through a systematic literature review.
Methods: A systematic search of MEDLINE® and Embase® with back-referencing and supplementary literature searches
was performed to retrieve data from interventional and non-interventional studies on the humanistic burden of
Pompe disease. Publications were screened according to predefined criteria, extracted, and assessed for quality.
Extracted data were narratively synthesized.
Results: No publications on the humanistic burden of infantile-onset Pompe disease (IOPD) were identified.
As such, of 17 publications included here, all are in patients with late-onset Pompe disease (LOPD). Thirteen
publications were initiated after approval of ERT, two were initiated before, and two overlapped the approval
of ERT. The review shows that LOPD patients have a significantly lower HRQoL than the general population,
even if treated with ERT. On transitioning to ERT, treatment was associated with improvement in the physical
component score of the SF-36 and fatigue, although the SF-36 mental component score remained stable.
Physical HRQoL remained below population norms after 4 years of ERT. Significantly more ERT-treated patients
reported pain than controls, and bodily pain worsened in later years following ERT initiation. Treatment-naïve
LOPD patients had significantly poorer ADL functioning compared with the general population, although ERT
stabilized deteriorating functioning impairment. ERT studies showed caregivers provide 17.7 h/week informal
care on average. Fifty percent, 40% and <20% of caregivers reported mental health, physical health, and financial/
relational problems, respectively. In ERT-naïve patients, wheelchair use and home ventilatory support was associated
with lower physical HRQoL and ADL functioning. In ERT-treated patients, key factors predicting worse HRQoL and ADL
functioning were higher respiratory distress, poorer sleep quality, greater pain, and more fatigue.
Conclusions: Pompe disease has a substantial humanistic burden, with strong inter-relationships among and between
humanistic burden parameters and clinical progression.
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Background
The humanistic burden considers the impact of an ill-
ness on a patient’s health-related quality of life (HRQoL),
activities of daily living (ADL), caregiver health, and
caregiver QoL. The humanistic burden also takes into
account patients’ treatment satisfaction and adherence
to their specific treatment regimen.
Pompe disease is an autosomal recessive, progressive,
debilitating disease in which acid α-glucosidase (GAA)
deficiency leads to intralysosomal accumulations of
glycogen in all tissues. All muscle groups are affected,
including ventilatory, cardiac, and skeletal muscles, and
there is some evidence of motor neuron dysfunction and
pathology of the central and peripheral nervous systems
[1–3], with resultant effects on cognitive function,
hearing loss, speech muscle pathology, and fine motor
dysfunction in patients with classic-infantile Pompe
disease.
Pompe disease presents as a wide spectrum of pheno-
types, ranging from the severe, rapidly progressive
infantile-onset Pompe disease (IOPD) to the more slowly
progressing late-onset Pompe disease (LOPD) that can
manifest any time from early childhood to late adult-
hood [4–6].
Clinically, infants with IOPD typically present during
the first few weeks of life with hypotonia, progressive
weakness, macroglossia, hepatomegaly, and hypertrophic
cardiomyopathy. This presentation usually facilitates iden-
tification of the disorder [7, 8]; however, identifying LOPD
can be more challenging as these patients generally
present with slowly progressive limb girdle-type weakness
and ventilatory insufficiency without significant cardiomy-
opathy. Cardiac involvement in LOPD has been described,
and may manifest as Wolff-Parkinson-White syndrome,
left ventricular hypertrophy, and dilatation of the ascend-
ing aorta [9, 10]. Rigid spine syndrome, scoliosis, and low
body weight have also been reported in some patients with
LOPD that have onset in adolescence, resulting in postural
anomalies [7–9]. The laboratory diagnosis of Pompe
disease depends on the measurement of GAA activity in
the blood or tissues, or the detection of disease-causing
variants in the GAA gene.
Pompe disease is a rare condition. The reported preva-
lence estimates vary widely depending on ethnicity and
diagnostic approach used [5, 11], and there is a lack of
accurate, consistent estimates for both IOPD and LOPD
in the published literature; however, for Europe the esti-
mated prevalence of Pompe disease is about 1 in
283,000 [11]. Based on predictions from carrier frequen-
cies, newborn screening data, and retrospectively regis-
tered data, the frequency of IOPD has been estimated
between 1 in 8684 to 138,000 worldwide [12–14].
Currently, the only specific drug treatment for Pompe
disease is ERT with recombinant human GAA (rhGAA),
which was approved for use in the United States (US)
and Europe in 2006 [15]. A recent systematic review and
meta-analysis demonstrated a nearly five-fold reduction
in mortality rates over an average study duration of ap-
proximately 46 months in patients treated with ERT
compared with untreated patients (rate ratio: 0.21; 95%
credible interval [CrI]: 0.11–0.41) [6]. This meta-
analysis also reported a benefit of ERT in terms of
slowing pulmonary functioning decline and improving
6-min walk test (6MWT; the distance an individual is
able to walk in 6 min) results. While ERT as the
principal treatment targeting the underlying pathology
in Pompe disease has transformed the lives of pa-
tients, supportive care has an important ongoing role
in the management of the condition.
Several limitations of ERT remain, including (1) de-
pendency on high infusion volume, time-consuming
infusions at least every other week [4, 15], (2) as-
sociated adverse infusion reactions in some patients
[4, 15], (3) the inability to clear neuronal glycogen,
with subsequent pathology progression and functional
decline [16–18]; (4) the reappearance of glycogen in
satellite cells [16–18]; (5) continued autophagic build-
up in tissue [19]; and (6) antibody responses to ERT
that mitigate the efficacy of ERT [20]. These limita-
tions, along with the non-recoverable muscle function
loss from Pompe disease, lead to a substantial burden
of illness, both for treated and untreated patients.
When investigating the overall burden of a disease,
clinical manifestations and economic costs tend to cap-
ture the greatest interest of clinicians and payers and
garner the focus of most research effort. However, the
humanistic burden of a disease, rather than its clinical
and economic burden, is typically of greatest concern to
patients and their caregivers. Although several reviews
have previously been published on the clinical burden of
Pompe disease [4–6, 8], the overall humanistic burden
has been neglected. This article aims to characterize all
aspects of the humanistic burden of Pompe disease and
of ERT through a systematic review of the relevant
literature for both IOPD and LOPD.
Methods
No ethical approval was required because no individual
patient identifiers were disclosed in the publications con-
tained in this systematic literature review. A PRISMA
2009 Checklist [21] and a review protocol summary are
provided as Additional Information.
The following research questions were formulated by
the authors at the start of this analysis:
 What is the impact of Pompe disease on humanistic
burden in patients receiving ERT throughout the
course of clinical studies (both observational and
Schoser et al. BMC Neurology  (2017) 17:202 Page 2 of 17
interventional), and in patients transitioning from
supportive treatment to ERT during the course of a
clinical study?
 What inter-relationships exist among humanistic
burden parameters in Pompe disease?
 How does the humanistic burden change as the
disease progresses?
 What is the impact of ERT on the humanistic
burden of Pompe disease?
Search strategy
Systematic searches were performed in Embase®/MED-
LINE® using Embase.com® to identify relevant articles
published through July 2016 on the humanistic burden
(patient HRQoL, ADL, caregiver burden, treatment sat-
isfaction and adherence) of Pompe disease. Each search
was conducted using controlled vocabulary and key
words, and was limited to articles published in English
and involving human subjects (as is standard practice
for literature reviews of this kind). The specific search
terms used are provided as Additional Information.
Additional publications were identified through bibliog-
raphy reviews of relevant articles as well as supplemen-
tary searches using Google, Google Scholar and other
web-based sources.
Selection criteria
Titles and abstracts of articles identified were carefully
screened by the authors in the initial review for relevance
to the topic. Articles were selected for inclusion based on
predefined acceptance criteria, which included patient
population (adults/children diagnosed with Pompe dis-
ease), outcome measures of interest (HRQoL, ADL, care-
giver burden, treatment satisfaction, and treatment
adherence), and study design (quantitative and/or qualita-
tive data collection). Articles exclusively reporting clinical
and/or economic outcomes were excluded, along with
those in a non-English language and with an absence of
peer-review for articles, editorials, correspondence, and
conference abstracts.
Potentially relevant articles were obtained in full-text for
further evaluation. Each was screened and its eligibility
confirmed by two reviewers. Inconsistencies were resolved
through consensus.
Quality assessment
A descriptive analysis of each publication was conducted
during data extraction. Each publication was assessed
for quality by considering characteristics that could
introduce bias, using the following tools: 1) Newcastle-
Ottawa Scale for cohort studies and case-control studies
[22]; 2) Adapted Newcastle-Ottawa Scale for cross-
sectional studies [22]; 3) AMSTAR measurement tool
for reviews [23]; 4) Cochrane risk of bias assessment tool
for randomized controlled trials [24].
Data extraction
Data from the included studies were extracted into a
predefined extraction grid by a single reviewer. Informa-
tion was recorded for study design, setting, patient char-
acteristics, outcome measures, key results, and
conclusions. A description of the outcome scales used in
the studies included in this review is provided in Table 1.
Given the descriptive nature of this systematic review,
the extracted data were narratively synthesized.
Results
Overview
Titles and abstracts of a total of 352 citations were
screened following the initial searches, 36 of which were
included for full-text screening. Seventeen articles were
subsequently selected for final inclusion in the narrative
synthesis (Fig. 1). The basic characteristics and quality
ratings of the included studies reporting data on the hu-
manistic burden of Pompe disease are shown in Table 2.
All 17 publications included patients with LOPD. Im-
portantly, no studies on the humanistic burden of IOPD
were identified, demonstrating a gap in the literature.
The 17 LOPD publications included six prospective co-
hort studies [25–30], one randomized controlled trial
(RCT) [31], eight cross-sectional studies [32–39], and
two case series [40, 41].
Five of the 17 publications are based on separate ana-
lyses of the International Pompe Survey, a long-term
prospective natural history study initiated 4 years prior
to the approval of ERT and continuing today [29, 30, 32,
33, 36]. This survey was established to collect informa-
tion on the course of the disease and its burden on pa-
tients, and includes patients from Australia, Germany,
the Netherlands, the United Kingdom (UK), and the
United States of America (US).
Thirteen publications included in this systematic re-
view are based on clinical studies that were initiated
after the approval of ERT [25–28, 31, 34–41]; conse-
quently, all participants were receiving open-labeled
ERT throughout the course of these studies. Two
publications published before ERT approval describe
participants treated in the absence of ERT [32, 33].
Finally, two publications [29, 30] are based on studies
that were initiated before ERT approval and continued
into the ERT era; therefore, these studies include pa-
tients who were not receiving ERT at study onset but
transitioned to ERT during the study.
In addition to the complete absence of publications
reporting on the humanistic burden of IOPD, this review
did not identify any LOPD studies describing treatment
satisfaction or adherence. Therefore, the following
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Table 1 Description of outcome scales used in studies in this review
Scale Description Range Interpretation
Brief pain
inventory (BPI)
Measures both the intensity of pain (sensory
dimension) and interference of pain in the
patient’s life (reactive dimension); it also queries
the patient about pain relief, pain quality, and
patient perception of the cause of pain
Scores range from 0 (no pain) to
10 (pain as bad as you can imagine)
A higher score indicates greater pain
Pain interference
score (PIS)
Average score of four items on the BPI devoted
to severity of pain
Scores range from 0 (does not
interfere) to 10 (completely
interferes)
A higher score indicates greater
interference of pain
Pain severity score
(PSS)
Calculated on the basis of the average
interference of pain (assessed on the BPI) with
the following seven activities: general activities,
mood, walking ability, normal work, relations
with other people, sleep, and enjoyment of life
Scores range from 0 (no pain) to
10 (pain as bad as you can imagine)
A higher score indicates greater pain
CarerQoL Measure of care-related QoL in informal care
givers; comprising two parts: a description of
the care situation on seven burden dimensions
(CarerQoL-7D) and a valuation component in
terms of general QoL using a Visual Analog
Scale (CarerQol-VAS)
Assesses the overall well-being of
the caregiver on a 0–10 scale, ranging
from “completely unhappy” (0) to
“completely happy” (10)
A higher score indicates greater
happiness
Fatigue severity
scale (FSS)
Self-reported nine-item questionnaire
concerning the respondent’s fatigue; for
example, how fatigue affects motivation,
exercise, physical functioning, carrying out
duties, interfering with work, family or
social life
Participants grade each question on
a Likert scale from 1 to 7, where 1
indicates strong disagreement and 7
indicates strong agreement
A higher score indicates more severe
fatigue. Scores above 4 indicate
significant fatigue and scores above
5 indicate severe fatigue
Hospital anxiety
and depression
scale (HADS)
14-item self-rated scale. Seven of the items
relate to anxiety and seven relate to
depression. Each item is rated from 0 to 3,
where 0 = not at all to 3 =most severe
Depression and anxiety scores can
each range from 0 to 21
Higher scores indicate greater anxiety
or depression
Nottingham health
profile (NHP)
Assesses subjective health status Ranges from 0 (good) to 100 (poor) Higher scores indicate poorer health
status
Pittsburgh sleep
quality index
(PSQI)
19 self-rated questions and five questions rated
by the partner. The latter five questions are
used for clinical information only and are not
tabulated in the scoring of the PSQI. The 19
self-rated questions assess a wide variety of
factors relating to sleep quality, including
estimates of sleep duration and latency, and
the frequency and severity of specific sleep-
related problems
Global PSQI score is calculated from
the responses given using a predefined
algorithm, and ranges from 0 to 21
A higher score indicates worse sleep
quality
Rotterdam
handicap scale
(RHS)
Used to measure a patient’s functional ability
and level of handicap, and can be used to
monitor a patient’s status over time as well as
to evaluate the effectiveness of interventions
Scores per item range from 1 (‘unable
to fulfill the task or activity’) to 4
(‘complete fulfillment of the task or
activity’). The total score is derived by
adding individual component scores
and ranges from 9 (‘unable to fulfill any
task/activity’) to 36 (‘able to fulfill all
applicable tasks or activities’)
A higher score indicates better
functional ability
Short-form-36
(SF-36)
Multidimensional HRQoL instrument
comprising four physical health scales (physical
functioning, role limitations due to physical
problems, bodily pain, and general health
perceptions) and four mental health scales
(vitality, social functioning, role limitations due
to emotional problems, and mental health).
These eight scales can be aggregated into
two summary measures: the physical (PCS)
and mental (MCS) component summary scores
Each scale is directly transformed into
a 0–100 scale on the assumption that
each question carries equal weight
A lower score indicates greater
disability (i.e., a score of zero is
equivalent to maximum disability
and a score of 100 is equivalent to
no disability)
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analysis focuses on the impact of LOPD on humanistic
burden, and is structured according to the predefined re-
search questions outlined above.
LOPD is associated with substantial humanistic burden
This section focuses on the overall reported humanistic
burden of LOPD, both in the absence and presence of
ERT.
HRQoL
Overall HRQoL burden was described in four studies;
one in the absence of ERT [32], two among patients
treated with ERT [26, 34], and one RCT in which pa-
tients were randomized to either placebo or ERT [31].
HRQoL was typically measured using the 36-item Short-
Form Survey (SF-36) (Table 1).
Hagemans et al. [32] reported a cross-sectional ana-
lysis of the International Pompe Survey in 210 patients
with LOPD, prior to approval of ERT. Patients presented
with a wide range of disease severity, from the mildly af-
fected to wheelchair- and ventilator-dependent, and re-
ported significantly poorer HRQoL on the physical
functioning, physical role functioning, general health, vi-
tality, and social functioning subscales of the SF-36 than
the general population (p < 0.001 on all scales). The
difference was most profound for the physical function-
ing scale, with an adjusted mean score among patients
of 29.3, compared with 83.1 (standard deviation [SD]
not reported) in the general population. No significant
differences were found for the bodily pain, emotional
role functioning, or mental health scales, which, the au-
thors speculated may have reflected the slow progression
of limitations in daily activities, allowing patients to
adapt over time to their situation and adjust their expec-
tations. In a subset of 38 Dutch patients, the authors
compared SF-36 scores at baseline and after 1 year; par-
ticipants were asked on a 5-point scale whether their
physical situation had improved a lot, improved a little,
remained the same, deteriorated a little, or deteriorated
a lot. Twenty-seven of the 38 participants reported de-
terioration in their physical situation, while none re-
ported improvement. No significant differences were
seen for any of the SF-36 subscales between the two
time points. The authors suggested that either changes
in the physical situation were not always accompanied
by changes in QoL or that, as a generic QoL instrument,
the SF-36 was insufficiently sensitive to capture such
changes.
van der Ploeg et al. [31] reported data from the Late
Onset Treatment Study (LOTS), an RCT of 90 LOPD
Fig. 1 Flowchart of screening and identification process
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patients aged 8 years or older, ambulatory, and free of
invasive ventilation, who received ERT or placebo for
78 weeks. All patients had substantially diminished
SF-36 physical component summary (PCS) scores at
baseline (ERT-treated patients, 34.3 ± 8.9; placebo-
treated patients, 34.9 ± 7.2), which were more than 1.5
SD below the norm for the US general population
(50 ± 10). Importantly, despite treatment with ERT,
the mean SF-36 PCS score did not increase signifi-
cantly over the 78-week study ([35.1 ± 9.9], change
[95% CI], 0.80 [−1.22 to 2.82]).
Boentert et al. [34] presented a cross-sectional analysis
in which 60 of 65 German patients received ERT (mean
ERT duration, 5 years), while Aslan et al. [26] described
a prospective cohort study of nine Turkish LOPD pa-
tients receiving ERT, who participated in an inspiratory
muscle training (IMT) program to improve QoL.
Boentert et al. stated (without providing quantitative
data) that despite ERT, LOPD patients had significantly
lower HRQoL than the general population, based on the
SF-36 subscales for physical functioning, physical role
limitation, general health perception, vitality and social
functioning. Aslan et al. also reported impaired HRQoL
despite ERT, using the Nottingham Health Profile
(NHP), which assesses subjective health status on a scale
from 0 (good) to 100 (poor). At baseline, subscales of
the NHP ranged from 15.7 for emotional reaction to
82.8 for physical ability. Following implementation of
IMT, this study reported improvement in social isolation
from 22.5 (interquartile range, 53.8–100.0) to 0.0 (0.0–
16.9) (p = 0.02), but no other HRQoL subscale demon-
strated a treatment response. This led the authors to
speculate that participation in the IMT program and the
associated weekly telephone contact may have been
responsible for the improved social isolation scores.
Patient-reported symptoms
This section describes patient-reported symptoms (PRS)
that were reported alongside HRQoL, ADL, caregiver bur-
den, treatment satisfaction and adherence. This is included
because studies reporting on humanistic parameters fre-
quently also describe common symptoms of Pompe disease
(most notably pain, fatigue, and sleep disorders) with a con-
siderable negative impact on humanistic burden. A system-
atic review of PRS was beyond the protocol-defined
objectives of this review because PRS is typically classified
under clinical burden.
Patient-reported symptoms were discussed in two
publications in the absence of ERT [30, 32], and five
publications in the presence of ERT [26, 34, 36, 38, 39].
In Hagemans et al. [32], where no ERT was available,
excessive daytime sleepiness (EDS) was reported in ap-
proximately 25% of patients and sleep disturbances were
reported in more than 40% of patients. In a later analysis
of the same study, van der Meijden et al. [30] found that
78% of patients experienced fatigue (Fatigue Severity
Scale [FSS] score ≥ 4), and 67% reported severe fatigue
(FSS score ≥ 5).
Patients receiving ERT also had poor sleep quality, as
assessed by Aslan et al. [26] using the Pittsburgh Sleep
Quality Index (PSQI) to measure the quality and pat-
terns of sleep during the previous four weeks. Among
these patients, there was a median (interquartile range)
total score of 5.0 (2.0–10.5; a cut off score of 5 or more
distinguishes ‘bad sleepers’). Introduction of IMT did
not improve sleep quality. Boentert et al. [34] also re-
ported sleep symptoms, noting that 45.2% of patients
were bad sleepers according to the PSQI (mean PSQI
global score, 6.2 ± 3.7). Scores for sleep disturbances,
sleep quality impairment and reduced daytime per-
formance were the highest of the PSQI component
scales. EDS was reported by 24.6% of patients (mean
ESS, 6.9 ± 4.3).
In addition, Boentert et al. also presented respiratory
symptoms, reporting that morning headache was re-
ported by 40.0% of patients (‘occasional’ 35.4%; ‘often’
4.6%) [34]. Nocturnal dyspnea was specified as ‘occa-
sional’ by 18.5% of patients and as ‘often’ by 6.2%.
Orthopnea was reported by 60.0% of patients, resting
dyspnea in the upright position by 4.6%, and exertional
dyspnea by 93.8% of patients. Dyspnea was reported in
29.2%, 40.0% and 24.6% of patients on mild, moderate
and heavy exercise, respectively.
A cross-sectional study in 57 German adult LOPD pa-
tients (84% on ERT) and 57 controls reported the impact
of urge incontinence and gastrointestinal symptoms
[39]. In this study, stool urgency, diarrhea, and urinary
urge incontinence were reported significantly more fre-
quently in patients compared with the age- and gender-
matched controls (55%, 56%, 33% vs. 20%, 18%, 7%).
In a cross-sectional analysis from Germany and the
Netherlands from the International Pompe Survey, Gün-
gör et al. [36] assessed the presence and severity of pain
in 124 adult LOPD patients, 101 of whom were receiving
ERT (median ERT duration, 4 years). They noted that a
significantly greater proportion of ERT-treated LOPD
patients reported pain compared with unaffected con-
trols (45% vs. 27%, respectively; p = 0.004) on the Brief
Pain Inventory (BPI) (Short-Form). In this study, the me-
dian pain severity score (PSS) – calculated from the BPI
(Table 1) – was higher (worse) among patients than con-
trols reporting pain in the previous 24 h (median PSS
3.1 [range 0.75–8] vs. 2.6, [range 0.75–5.25], respectively;
p = 0.06). Similarly, the pain interference score (PIS; also
calculated from BPI), was significantly higher (worse) in
patients than controls (median PIS 3.3 [range 0–8.4] vs.
1.3 [range 0–4.4] respectively; p = 0.001). Pain particu-
larly interfered (PIS score ≥ 4) with patients’ general
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activities, walking, and normal work, and showed a mild
interference (PIS score ≥ 3) with mood, sleep, and enjoy-
ment of life. For each of the seven domains of daily life,
PIS scores were significantly worse in LOPD patients
than controls, except for interference with sleep. The
authors concluded that while pain is not the most prom-
inent symptom of Pompe disease, it is a common and
debilitating aspect of the disease that merits identifica-
tion and management in this population.
In a follow-up to this study, the same group surveyed
25 patients from the UK using the long-form of BPI,
which assesses pain over the previous 7 days [38]. This
study reported that 88% of patients reported pain in the
last week, a considerably higher proportion than the
45% reporting current pain in Güngör et al. [36]. Median
PSS (3.9 [0.5–7.5] vs 3.1 [0.75–8.0]) and median PIS (3.9
[0–7.5] vs 3.3 [0–8.4]) were only slightly higher (worse)
in this paper than in the publication by Güngör et al.
[36, 38]. These data reinforce the troublesome nature of
pain in LOPD.
ADL
The International Pompe Survey is the primary source
of data on ADL burden [33]. This cross-sectional ana-
lysis was conducted in 257 patients with treatment-naïve
LOPD (across a broad range of severity) with a median
age of onset of 38 years. The impact of LOPD on partici-
pation in ADL was assessed using the Rotterdam Handi-
cap Scale (RHS). The mean RHS score among patients
in this study was 25.9 ± 6.5 (median, 27), compared with
a maximum of 36, which would be scored by a healthy
person. Mean RHS scores ranged from 25.5 in Germany
to 27.7 in France, but the differences between countries
were not statistically significant. Highest scores (reflect-
ing least restrictions) were found for ‘mobility indoors’
and ‘leisure activities indoors’, while the lowest scores
were found for ‘domestic tasks indoors’, ‘domestic tasks
outdoors’, and ‘work/study’. The authors suggested that
their findings demonstrate the considerable impact of
Pompe disease on patients’ everyday life experiences.
Caregiver burden
One publication so far examined caregiver burden in
LOPD [37]. This Dutch study was conducted among 67
patients with LOPD and their caregivers. Caregivers
were most often partners (92%), while for children,
parents were generally the primary caregivers (94%).
Fifty-nine of the 67 patients were receiving ERT.
Caregivers provided about 17.7 h per week of informal
care, with some variation (SD 27.5) [37]. Adults prima-
rily received maintenance for household activities (48%
of time) and only limited for personal care (18%). In
pediatric patients, informal care given as personal care
(32% of time) and social activities (36%) was most
significant. No caregiver time was spent on specific
nursing activities in both age groups. Informal care was
provided at the expense of the caregiver’s leisure or work
time. The majority (97%) of caregivers gained ‘some sat-
isfaction’, while up to 60% gained a ‘lot of fulfillment’ for
providing care. 50% of caregivers reported mental health
problems, while 40% had physical health problems. The
average burden for caregivers was 3.2 (range, 0.0 to 8.9),
measured on a self-rated Visual Analog Scale (VAS, ran-
ging from 0 [not at all straining] to 10 [too much strain-
ing]). The mean burden of caregiving for patients below
the age of 18 years was higher than for adults (4.1 versus
2.9 respectively; p = 0.075). Caregiver burden for patients
with LOPD was relatively mild and well-being was not
far below the population norms.
Strong inter-relationships exist among humanistic burden
parameters
Beyond humanistic burden overall, the association be-
tween individual parameters of humanistic burden was
also investigated. Data on these relationships in the ab-
sence and presence of ERT are taken primarily from the
four studies, previously described [33, 34, 36, 37].
Poorer HRQoL is associated with increased fatigue, reduced
sleep quality, and increased pain
In Boentert et al. [34], fatigue among ERT-treated
LOPD patients was assessed using the FSS and sleep
quality was measured using the PSQI. In this analysis,
the PCS and MCS of the SF-36 were both inversely
correlated with the FSS score (PCS, r = −0.46, p <
0.001; MCS, r = −0.44, p < 0.01) and the PSQI global
score (PCS, r = −0.38, p < 0.001; MCS, −0.47, p <
0.001). In terms of the impact of pain on HRQoL,
Güngör et al. [36] reported that ERT-treated patients
with pain had significantly lower physical (median
PCS score 30 [range, 11–45] vs. 35 [range, 17–58],
respectively; p < 0.001) and mental HRQoL (median
MCS scores 54 [range, 29–74] vs. 58 [range, 29–71],
respectively; p = 0.049) than those without pain.
Poorer HRQoL (except the mental health domain) is
associated with greater functional disability
The relationship between the RHS and the SF-36 was in-
vestigated in the absence of ERT by Hagemans et al.
[33]. The RHS correlated significantly with all SF-36
subscales except for the mental health domain. The lar-
gest positive correlation of RHS (r = 0.83, p < 0.001) was
found with the physical functioning subscale of SF-36.
Poorer HRQoL is associated with greater caregiver burden
Kanters et al. [37] reported a significant, inverse cor-
relation between patient HRQoL and both caregiver
burden and the volume of care provided (rho = −0.430
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and rho = −0.465, respectively; p < 0.001 in both cases)
in ERT-treated patients. Patients with the lowest
HRQoL (lowest quartile) received 35.1 h of care per
week, with a caregiver burden of 5.3 on the self-rated
burden scale, whereas patients with HRQoL in the
highest quartile received only 3.9 h of care per week,
with a lower caregiver burden of 2.3 on the self-rated
scale.
Greater functional disability is associated with greater
fatigue, poorer sleep quality, and increased pain
Boentert et al. [34] found that the functional ability of
ERT-treated patients (measured using RHS) was inversely
correlated with fatigue (FSS, r = −0.40, p < 0.01) and sleep
disturbance, (PSQI, r = −0.46, p < 0.001). Similarly, Güngör
et al. [36] reported that ERT-treated patients with pain
had lower functional abilities based on median RHS scores
than those without pain (26 [range, 15–36] vs. 28 [range,
16–36], respectively; p = 0.02).
Greater sleep disturbance is correlated with increased
fatigue
Boentert et al. [34] reported, unsurprisingly, that PSQI
global score was positively correlated with FSS score
(r = 0.33, p = 0.01) in the presence of ERT, indicating
that fatigue increased with greater sleep disturbance.
Increased pain is associated with increased depression and
anxiety
Güngör et al. [36] found that ERT-treated patients with
pain had significantly higher levels of depression and
anxiety than those without pain. Anxiety and depression
were measured using the median Hospital Anxiety and
Depression Scale (HADS), with higher scores indicating
greater anxiety or depression. HADS anxiety score
among patients reporting pain was 5 (range, 0–15) com-
pared with 3 (range, 0–12) among patients with no pain
(p = 0.003), while the HADS depression score was 5
(range, 0–13) and 3 (range, 0–12) for patients with and
without pain, respectively (p = 0.005).
Clinical progression of disease is strongly associated with
greater humanistic burden
We investigated the impact of clinical progression on
humanistic burden using data from four studies
described previously [32–34, 37].
Wheelchair use is associated with decreased HRQoL, greater
functional disability, and greater caregiver burden
Hagemans et al. [32] found that wheelchair use is associ-
ated with lower HRQoL and ADL scores. In their 2004
study, untreated patients who used a wheelchair scored
on average 23.6 points lower on the physical functioning
scale and 15.1 points lower on the social functioning
scale of the SF-36 than patients who did not need a
wheelchair (regression coefficient (B) = −23.6 and −15.1,
p < 0.001) [32]. In their 2007 study, Hagemans et al. [33]
reported significantly lower mean RHS scores in patients
who used a wheelchair than those who did not (20.9 vs.
29.5, respectively; p < 0.001).
Kanters et al. [37] reported that ERT-treated wheel-
chair users received significantly more hours of informal
care than patients who were not wheelchair-dependent
(25.6 h vs. 14.0 h, respectively; p < 0.001). As such, care-
giver burden was significantly higher (self-rated scale,
5.1 vs. 2.4, respectively; p = 0.002) and caregiver well-
being was significantly lower (CarerQoL-VAS, 6.4 vs. 7.5,
respectively; p = 0.024) for patients who used a wheel-
chair than those who did not.
Increased respiratory distress is associated with poorer
HRQoL, greater functional disability, and greater sleep
disturbance and fatigue
An association between increased respiratory symptoms
and poorer HRQoL (both physical and mental compo-
nents) among ERT-treated patients was reported by Boen-
tert et al. [34]. Respiratory symptoms were quantified
using the respiratory symptoms questionnaire (RSQ), in
which a low score indicates less frequent respiratory
symptoms. Both the PCS score and the MCS score were
negatively correlated with the RSQ score (PCS, r = −0.25,
p < 0.05; MCS, r = −0.46, p < 0.001). This finding is con-
sistent with data from untreated patients reported by
Hagemans et al. [32], in which reduced respiratory distress
was significantly associated with higher HRQoL.
Boentert et al. [34] also found that higher levels of
respiratory distress were associated with greater sleep
disturbance, as demonstrated by a positive correlation
between PSQI and RSQ scores (r = 0.43, p < 0.0001).
Fatigue, measured using the FSS, was also positively as-
sociated with respiratory distress, assessed using the
RSQ (r = 0.58, p < 0.0001), while respiratory distress and
functional ability were inversely related, with RHS scores
strongly associated with both upright and supine forced
vital capacity (FVC) (r = 0.62 and r = 0.69, respectively, p
< 0.001). Similar findings were observed in the absence
of ERT, with Hagemans et al. [32] reporting that the
need for home ventilatory support was associated with
lower physical functioning scores (B = −8.4, p = 0.004),
and that mean RHS scores were significantly lower in
patients receiving respiratory support than those without
it (22.9 vs. 28.5, p < 0.001). Among the patients who used
respiratory support, the correlation between the number
of hours of ventilation and the RHS score was −0.59 (p
< 0.001), suggesting a reduction in functional ability with
increasing use of ventilation. Consistent with this, in this
study, almost all patients requiring more than 12 h of
ventilation per day required a wheelchair.
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Cardiopulmonary distress is associated with increased
fatigue in male patients
Boentert et al. [34] assessed the relationship between
fatigue and “cardiopulmonary distress” in patients re-
ceiving ERT, as measured using the 6MWT and FVC.
It should be noted that 6MWT and FVC are not dir-
ect measures of cardiopulmonary distress; the 6MWT
in particular reflects various aspects of physical func-
tioning and may be influenced by cardiac function,
walking ability, and respiratory muscle strength. The
FSS score was inversely correlated with the 6MWT
(r = −0.35, p < 0.01) (meaning that patients with more
severe fatigue performed less well on the 6MWT),
but surprisingly, this negative correlation was only
apparent in the male subgroup (r = −0.53, p < 0.01),
indicating that fatigue in female patients may be inde-
pendent of motor performance.
ERT is associated with short-term stabilization of human-
istic burden
Here, we consider the impact of ERT on the principal
aspects of humanistic burden. No data describing the
impact of ERT on caregiver burden were identified.
HRQoL
Seven articles describe the impact of ERT on HRQoL in
LOPD (Table 2) [25, 27–29, 31, 35, 39]: van der Ploeg et
al. (2010) reported results from LOTS [31] (discussed
above); Güngör et al. [29] evaluated 174 untreated
patients who transitioned to ERT during the study;
Angelini et al. [25] describe clinical response and
changes in functional ability in a prospective cohort
study of 11 adult patients; Strothotte et al. [28] and
Regnery et al. [27] report data from an open-label obser-
vational trial in 44 and 38 adult patients, respectively, in
Germany over periods of 12 and 36 months Freedman et
al. [35] present a cross-sectional analysis of seven fam-
ilies of young patients (age not specified) with LOPD in
Australia, using semi-structured interviews; and van
Capelle [41] reports a case series of two children and
one adult with LOPD treated with ERT in the
Netherlands.
As reported earlier, van der Ploeg et al. found that un-
treated patients with LOPD had lower SF-36 scores at
baseline, which did not improve significantly over
78 weeks’ treatment with ERT [31]. Similarly, Güngör et
al. [29], evaluated PCS and MCS components of the SF-
36 during three time periods: pre-ERT, first 2 years of
ERT, and after more than 2 years of ERT. Before ERT,
the PCS decreased significantly by 0.73 score points per
year (sp/y). This was followed in the first 2 years after
treatment by a significant increase of 1.49 sp./y, and by
stabilization thereafter. The MCS was generally stable
during the entire follow-up period. Throughout
treatment follow-up, the physical functioning, physical
role, general health and vitality domains improved, with
particularly large increases during the first 2 years of
ERT in physical role (9 sp./y), general health (5 sp./y)
and vitality (4 sp./y), and a renewed decline thereafter.
Mental health domain scores increased in the first 2 years
of ERT (2 sp./y), and then declined, while social
functioning and emotional role did not improve with
treatment. The authors noted that the initiation of ERT
halted the progressive decline in physical health status
observed in the pre-treatment period, and argued that
improvements in the physical functioning and physical
role domains may be attributed to the positive effect of
ERT on muscle function and strength reported in other
studies.
A small prospective Italian study [25], described the
clinical response and changes in functional ability in 11
adult patients (age at onset 15–42 years), although re-
sults of SF-36 testing are reported in only three patients:
one had a mild improvement of mental health but not of
bodily pain; the second had no improvement in mental
health or role physical; and no HRQoL data are available
for the third patient who stopped treatment after
3 months following ERT-related adverse events. These
limited data are consistent with the open-label observa-
tional study of adult patients (mean age at onset 36 years)
in Germany [27, 28]. Here, patients showed no signifi-
cant longitudinal changes in HRQoL over the course of
either 12 or 36 months of ERT treatment [27, 28]. The
authors concluded that ERT stabilizes the chronic
progressive natural disease course of LOPD in some pa-
tients, although motor performance and lung function
still appear to decline in up to a third [27, 28].
Freedman et al. [35] reported on a cross-sectional
study that used qualitative interviews to assess ERT
response. They concluded that improved physical
health resulted in increased psychosocial well-being.
A benefit of ERT was also found by van Capelle et al.
[41] in SF-36 sub-domains for two of three patients
for whom these data were reported: one patient
showed improvements on the physical health and, to
a lesser extent, on the mental health domains, while
the other showed particular improvements on the
bodily pain and general health domains (no further
details provided). The methodology of these studies
(e.g., small sample size and reliance on qualitative in-
terviews) limits interpretation and generalizability of
their results.
Patient-reported symptoms
Data on the impact of ERT on fatigue and pain were
identified from the following four publications on hu-
manistic burden, as described above [25, 29, 30, 41].
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Fatigue In a 10-year analysis of the International Pompe
Survey evaluating 163 patients who transitioned to ERT
during the study [30], the proportion of patients report-
ing fatigue (FSS ≥4) fell from 85% at baseline to 79% at
the last follow-up (p-value not reported); the proportion
who were severely fatigued (FSS ≥5) fell from 68% to
55% (p-value not reported). Fatigue improved mainly in
women, patients aged 45 years or older, and those with a
disease duration less than 15 years. Improvement in fa-
tigue with length of ERT treatment was also reported by
van Capelle et al. [41] among two of three patients
studied.
Pain Güngör et al. [29] found that bodily pain worsened
in the years prior to ERT initiation, then improved for
2 years during ERT, before declining again after 2 years.
Interestingly, the authors also calculated the expected
bodily pain scores at three timepoints (4 years before
ERT, at start of ERT, and after 4 years of ERT) and re-
ported that the scores were more favorable than popula-
tion norms at all timepoints. No further details of this
analysis are provided. Data from Angelini et al. [25] were
available for two of the three patients who completed
SF-36 questionnaires; one reported mild improvement in
bodily pain on ERT initiation, while the second reported
no improvement.
In a clinical survey study, 45% of 124 LOPD patients
receiving long-term ERT (median ERT duration, 4
[0.07–12] years) reported having had pain in the previ-
ous 24 h, versus 27% of healthy adult controls (p =
0.004) [36]. Among patients who reported pain, the me-
dian PSS was 3.1 (indicating mild pain) and the median
PIS was 3.3 (indicating mild interference); these compare
with scores of 2.6 (p = 0.06) and 1.3 (p = 0.001) for PSS
and PIS, respectively, in controls. Relative to patients
without pain, those with pain had lower RHS scores (p =
0.02), lower SF-36 Physical and Mental component sum-
mary scores (p < 0.001 and p = 0.049), and higher levels of
depression and anxiety (p = 0.005 and p = 0.003). In this
largest study on pain, nearly one in two LOPD patients
had experienced pain in the previous 24 h. Although
pain severity and its interference with daily life was
mild, pain was related to a lower QoL, reduced par-
ticipation in daily life, and greater depression and
anxiety. Pain management should therefore be seen as
part of clinical practice involving Pompe patients [36].
ADL
The impact of ERT on patients’ ability to perform ADL
was reported in three studies, including Güngör et al.
[29] and van Capelle et al. [41] described previously. In
addition, information is taken from a Japanese case
series of five long-term, ventilator-dependent patients
with advanced LOPD (mean age of onset, 22 years),
which examined the efficacy of ERT over a 2-year period
[40].
In the International Pompe Survey [29], RHS scores
decreased significantly by a mean of 0.49 sp./y (95% CI,
−0.63 to −0.34) before ERT initiation and stabilized dur-
ing ERT treatment (−0.02 sp./y; 95% CI, −0.17 to 0.13).
No formal statistical comparisons between the two time
periods were provided for ADL. Subgroup analyses
showed that overall, RHS scores were better in less se-
verely affected than in more severely affected patients,
but the effects of ERT on the ADL of these subgroups
did not differ. Van Capelle et al. [41] reported improved
RHS scores over time for two of three adults receiving
ERT (from 16 and 18 after 3 years of ERT to 25 and 20,
respectively, after 8 years). Finally, Furusawa et al. [40]
assessed the impact of ERT on patient ADL through in-
terviews with patients and their families. Qualitatively,
the authors reported that all patients showed some im-
provements in ADL and in muscle function, while they
also argued that ERT elicited improvements in walking
distance and stabilization of pulmonary function. The
authors speculated that the improved muscle strength
resulted in the better ADL and HRQoL during the
follow-up period; however, no quantitative analysis was
provided to support this.
Discussion
Overview
Pompe disease is a rare and devastating condition for
both patients and their families. The clinical burden of
Pompe disease, including impact on survival and phys-
ical function, has been reviewed elsewhere [4–6, 8];
however, no systematic review on the humanistic burden
of Pompe disease has been published. Here, we present
the findings from 17 published papers and systematically
describe the humanistic burden of Pompe disease.
A major finding of this review is the complete
absence of data on the humanistic burden of IOPD,
precluding any discussion in this area. Further, al-
though 17 publications describe the humanistic bur-
den of LOPD, only two of these report studies
conducted in the absence of ERT, leaving a deficiency
in information on untreated patients. However, the
association of LOPD with the many measures of clin-
ical, functional, social and emotional well-being that
comprise the humanistic burden is reasonably well
documented, confirming the impact of LOPD on the
everyday life of patients and their caregivers. Al-
though the overall burden of LOPD is substantial for
patients, it is interesting to note that the impact on
caregivers reported in an isolated study [37] appears
to be relatively modest. This may be because families
do not consider it burdensome to care for loved ones
[42–44], or it may reflect adaptation to their family
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condition; LOPD is a slowly progressive, heteroge-
neous disease, and the context may be similar to
other chronic disorders or neuromuscular diseases,
where caregivers and patients adjust their expecta-
tions and priorities over time. This reinforces the
need to robustly study the impact of caring on fam-
ilies, and underscores the importance of examining
and understanding patients’ and caregivers’ perspec-
tives on the burden of illness, alongside traditional
clinical and economic investigations.
Our review demonstrates that clinical disease pro-
gression is strongly associated with greater humanistic
burden, and also shows strong correlations among in-
dividual humanistic burden parameters such as
HRQoL, ADL, and caregiver burden. Importantly,
ERT does not substantially improve this. Figure 2
(and its accompanying key) provides a graphical illus-
tration of correlations between humanistic and clinical
burden parameters in LOPD patients receiving ERT.
Unsurprisingly, deterioration in one parameter is
strongly linked to deterioration in another, and con-
tinues despite ERT. Although ERT provides some
benefit, the results appear to be modest, and patients
remain below population norms.
This ongoing burden of Pompe disease despite ERT
may be partly due, not only to the variety of muscle
groups affected, but also to pathology of the CNS and
PNS [1–3]. However, presently only brain autopsies in
untreated patients have shown clear evidence of glyco-
gen storage in the CNS [45, 46], and periventricular
white matter abnormalities on brain magnetic resonance
imaging (MRI) have been seen in children receiving ERT
[1]. Measuring the effects of CNS pathology on cognitive
function is confounded by co-occurring hearing loss,
speech muscle pathology, and fine motor dysfunction;
however, it is clear from emerging signs and symptoms,
which may be caused by neuronal glycogen deposition,
that ERT is unable to address all aspects of the disease
at least in infants with Pompe disease [3, 47–51]. While
ERT clearly slows disease progression for many patients,
available data demonstrate that it is limited in its ability
to improve and maintain clinical symptomatology and
associated disease burden in the long term. The reasons
for this are not fully understood, but given that improve-
ments in one facet of the disease burden are expected to
positively influence others, there is still substantial po-
tential for enriching patients’ lives beyond the response
currently achieved with ERT.
Evidence indicates that ERT leads to short-term
improvement and a mid-term stabilization of HRQoL,
although results have not been shown to persist in the
long-term so far. For example, in one study, there was
no improvement in mean SF-36 PCS scores over
78 weeks of treatment with ERT [31], while another
found that although ERT reversed a decline in SF-36
PCS, the benefit plateaued after 2 years without
Fig. 2 Inter-relationships between clinical, humanistic and economic burden parameters in LOPD patients receiving ERT
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normalizing; ERT appears to halt the decline in patients’
ability to perform ADL, but reports on ERT’s association
with improved functioning are mixed [29, 40, 41]. As
such, gaps remain in providing treatment options that
treat the underlying disease, improve clinical symptom-
atology, and positively affect patients’ abilities to lead
normal lives.
It is interesting to note that pain was reported by a
number of patients and interfered with their general ac-
tivities, walking, and normal work, as well as mood,
sleep and enjoyment of life [36]. While ERT temporarily
stabilized bodily pain, it did not reverse it; in fact, after
2 years of ERT, pain began to worsen once again [29].
The reason for this is not clear, but could be due to
neuronal deposition of glycogen, which cannot be
cleared by ERT [16, 17]. Given the substantial impact
pain has on people’s lives, further investigation is
warranted.
Gaps and limitations
Orphan diseases are hampered by lack of information
within the medical community and the scientific litera-
ture [52], and this is also true for our topic of review,
the humanistic burden of Pompe disease. For the most
severely affected patients – those with IOPD – the
humanistic burden of is unexplored, preempting any
comparisons between IOPD and LOPD. For LOPD, data
on the humanistic burden are comparatively extensive,
although significant gaps remain. Data were most robust
for HRQoL, the majority of which were generated after
ERT approval in 2006. There were very limited longitu-
dinal data on the progression of HRQoL, ADL and care-
giver burden in LOPD in both the presence and absence
of ERT, and no data on change in caregiver burden on
the introduction of ERT. In addition, across the entire
spectrum of disease severity, there are no data on patient
adherence and satisfaction with ERT.
Few studies examining humanistic burden parameters
were conducted before marketing approval was granted
for ERT, and their limited depth and breadth merit con-
sideration when interpreting this analysis. Similarly,
there is no published literature on patients who discon-
tinued ERT therapy, resulting in a lack of understanding
of how this affects patients. Data quality also limits this
systematic review; due to the rarity of Pompe disease,
many of the published studies are small, cross-sectional,
and lack the statistical robustness required to draw firm
conclusions. In addition, based on the screening criteria
employed, publications including relevant data only in
the body of the report but not in the title or the abstract
may have been overlooked, although attempts were
made to mitigate this through back-referencing and sup-
plementary searches. Finally, the possibility of double or
triple reported subjects cannot be excluded.
Avenues for future research
The introduction of ERT into the Pompe disease treat-
ment paradigm has reduced mortality and progression.
Nonetheless, the burden of the disease remains high,
and while the improved survival of many patients has
led to a shift in the ‘natural history’ to modified disease
stages and phenotypes, it has not led to a cure [6, 53].
Indeed, it is clear that ERT is unable to address all
aspects of this disease, particularly in terms of those
etiologies associated with neuronal glycogen deposition
[3, 47–51]. Crucially, substantial morbidity persists, and,
particularly in infants, mortality rates remain high at
28–43% [53–56]. Beyond an initial improvement, most
patients continue to decline, albeit at a slower rate than
untreated patients, and remain below population norms
[29]. Due to the time required to administer infusions,
ERT by itself is considered burdensome to patients and
caregivers [57]; whether this affects patient adherence
and satisfaction would also provide more context to the
understanding of the overall burden of Pompe disease.
Retrospective studies are generally inadequate for
collection of patient-reported humanistic data, such as
HRQoL, which are associated with significant recall bias
and limited to the preceding few weeks. It is important
to note that the young ages of patients with IOPD ne-
cessitates the use of caregiver-reported instruments to
accurately reflect the range and severity of the burden
across the spectrum of the disease; however, such ‘obser-
ver-reported outcomes’ are themselves associated with
bias. In addition, as the delay from diagnosis to treat-
ment shortens, it is becoming increasingly difficult to
capture the experience of untreated patients; in order to
do this; it is likely to be necessary to study patients in
countries that do not have access to ERT. Future colla-
borations with existing prospective studies, such as the
International Pompe Survey and the Pompe Registry,
may possibly enable further investigation of the impact
of ERT on the overall disease burden. However, to
understand the humanistic burden in detail, a long-term
observational study, focused specifically on the humanis-
tic burden of Pompe disease, may be necessary.
Alternative therapeutic approaches
There are alternative therapies under development for
Pompe disease that, if successful, may help address the
unmet medical need and the ongoing burden on the
everyday lives of patients and their families. These
include second generation ERTs that aim to improve
targeting and extracellular uptake of the recombinant
protein, either alone or in combination with pharmaco-
logical chaperones, to improve bioavailability and reduce
immunogenicity. Oligonucleotide therapeutics in the
form of mRNA-delivered GAA or exon-including anti-
sense RNA (for c.32-13 T > G splice site mutations in
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late-onset patients) are in development [58–60]. Further-
more, gene therapies (in vivo adeno-associated virus
[AAV] and Adenovirus, and ex vivo Lentivirus) are
another route of treatment, seeking to continuously and
endogenously produce GAA in target tissues and pos-
sibly minimize anti-GAA immunogenicity [61–64].
Thus, these new approaches may have the potential to
substantially improve patients’ clinical and humanistic
burden of disease, by resolving signs, symptoms and
progression previously resistant to treatment and
thereby improving patients’ HRQoL and ability to per-
form ADL. Given the increasing recognition of the im-
portance of understanding and capturing the patient
experience from patient and medical communities, as
well as regulatory and reimbursement authorities, it will
be key for new therapies to demonstrate not only their
ability to treat the clinical signs and symptoms, but also
to improve the day-to-day lives of patients and their
families [65–68].
Conclusions
This systematic review demonstrates that LOPD has a
substantial humanistic burden that is clearly associated
with clinical disease progression; patients with more se-
vere disease have increased fatigue, more pain, poorer
QoL, and less ability to perform ADL. Although ERT has
been shown to provide some benefit, patients remain well
below population norms. While there is a reasonable
amount of research published for LOPD, gaps remain, in-
cluding a complete absence of information on treatment
satisfaction or adherence, and little information on the hu-
manistic burden in the absence of ERT. For IOPD, the
lack of any published articles on the humanistic burden
represents a significant gap in the understanding of the
most severely affected patients. As such, these findings
point to an ongoing unmet need in the understanding of
Pompe disease. As new therapies are developed, it will be
critical to capture patients’ experiences and to further
study the effect that the disease, as well as the treatment,
has on both the clinical and humanistic aspects of Pompe
disease [69]. Only in this way, will we be able to fully
understand the effect that Pompe disease – and any po-
tential treatments – have on the overall lives of patients
and their families.
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